Successful corticosteroid-sparing effect of rituximab in the treatment of refractory idiopathic orbital inflammatory disease

4Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Idiopathic orbital inflammatory disease (IOID) is an idiopathic inflammatory process within the orbit that can result in permanent visual impairment. Although high-dose oral corticosteroids are currently the mainstay of therapy, their long-term usage can cause significant toxicity. We present a case of IOID that was successfully treated with the anti-CD20 monoclonal antibody rituximab following failed steroid sparing with conventional second-line immunosuppressive agents.

Cite

CITATION STYLE

APA

Shao, E. H., Karydis, A., Gemenetzi, M., & Taylor, S. R. J. (2013). Successful corticosteroid-sparing effect of rituximab in the treatment of refractory idiopathic orbital inflammatory disease. Case Reports in Ophthalmology, 4(3), 216–218. https://doi.org/10.1159/000356523

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free